Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.cgt.7700274PMID 11219495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

  2000cited by this paper
• Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis

  2000cited by this paper
• Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice

  2000cited by this paper
• Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications.

  2000cited by this paper
• A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.

  1999cited by this paper
• In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.

  1999cited by this paper
• Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

  1999cited by this paper
• In Vivo Tumor Suppression by Adenovirus-Mediated Interferon alpha2b Gene Delivery

  1999cited by this paper
• Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models

  1999cited by this paper
• Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

  1999cited by this paper
• Adenoviral Vectors Expressing Lymphotactin and Interleukin 2 or Lymphotactin and Interleukin 12 Synergize to Facilitate Tumor Regression in Murine Breast Cancer Models

  1999cited by this paper
• Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM

  1999cited by this paper
• Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

  1999cited by this paper
• Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18)

  1999cited by this paper
• Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.

  1999cited by this paper
• Type I consensus IFN (IFN-con1) Gene Transfer into KSHV/HHV-8-Infected BCBL-1 Cells Causes Inhibition of Viral Lytic Cycle Activation via Induction of Apoptosis and Abrogates Tumorigenicity in SCID Mice

  1999cited by this paper
• Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

  1998cited by this paper
• Recombinant E1-Deleted Adenovirus-Mediated Gene Therapy for Cancer: Efficacy Studies with p53 Tumor Suppressor Gene and Liver Histology in Tumor Xenograft Models

  1998cited by this paper
• Cancer vaccines

  1998cited by this paper
• Gene therapy for hepatic micrometastasis of murine colon carcinoma.

  1998cited by this paper
• A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.

  1998cited by this paper
• Safety profile of interferon-alpha therapy.

  1998cited by this paper
• Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors

  1998cited by this paper
• Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

  1998cited by this paper
• T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.

  1998cited by this paper
• Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model

  1998cited by this paper
• The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.

  1998cited by this paper
• In Vivo Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2

  1997cited by this paper
• Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1

  1997cited by this paper
• Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models

  1997cited by this paper
• Cytokines, tumour-cell death and immunogenicity: a question of choice.

  1997cited by this paper
• The potential applications of gene transfer in the treatment of patients with cancer: a concise review.

  1996cited by this paper
• The neglected role of type I interferon in the T-cell response: implications for its clinical use.

  1996cited by this paper
• Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression.

  1996cited by this paper
• Refolding, isolation and characterization of crystallizable human interferon-alpha 8 expression in Saccharomyces cerevisiae.

  1996cited by this paper
• A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

  1996cited by this paper
• Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy.

  1996cited by this paper
• Interferon-alpha hybrids.

  1995cited by this paper
• Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.

  1995cited by this paper
• Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

  1995cited by this paper
• Injection of irradiated b16 melanoma genetically-modified to secrete IFN-alpha causes regression of an established tumor.

  1995cited by this paper
• Role of interferons and other cytokines in the regulation of the immune response

  1995cited by this paper
• Cytokine therapeutics: lessons from interferon alpha.

  1994cited by this paper
• IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.

  1994cited by this paper
• Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.

  1993cited by this paper
• Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.

  1993cited by this paper
• Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice

  1991cited by this paper
• Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of friend erythroleukemia cells

  1988cited by this paper
• Studies on the expression of spontaneous and induced interferons in mouse peritoneal macrophages by means of monoclonal antibodies to mouse interferons.

  1987cited by this paper
• Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines.

  1987cited by this paper
• A deletion that includes the signal peptidase cleavage site impairs processing, glycosylation, and secretion of cell surface yeast acid phosphatase

  1984cited by this paper
• Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain.

  1982cited by this paper
• Progressive glomerulonephritis in mice treated with interferon preparations at birth

  1976cited by this paper

• The underlying mechanism and therapeutic potential of IFNs in viral-based cancers.

  2024cites this paper
• Study on the Recombinant Human Interferon α1b, α2b, and Gamma Transient Expression and in Vitro Activities in Tobacco

  2024cites this paper
• Use of IFN-Based Biotherapeutics to Harness the Host Against Foot-And-Mouth Disease

  2020cites this paper
• In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV‐driven tumours

  2014cites this paper
• Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines

  2014influential citation
• Novel Technologies for Vaccine Development

  2014cites this paper
• Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

  2012cites this paper
• Use of replication-defective adenoviruses to develop vaccines and biotherapeutics against foot-and-mouth disease

  2012cites this paper
• Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways

  2010cites this paper
• The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma.

  2010cites this paper
• The Antitumor and Immunoadjuvant Effects of IFN-α in Combination with Recombinant Poxvirus Vaccines

  2009cites this paper
• Adenoviral vector-based strategies for cancer therapy.

  2009cites this paper
• Interferon-α and cancer : Mechanisms of action and new perspectives of clinical use

  2007cites this paper
• Anti-angiogenic gene therapy of cancer: current status and future prospects.

  2007cites this paper
• Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

  2007cites this paper
• Detection of Differential Expression of Porcine IFN-α Subtypes by Reverse Transcription Polymerase Chain Reaction

  2007cites this paper
• Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma

  2006cites this paper
• Gene therapy of liver cancer.

  2006cites this paper
• Gene therapy of liver cancer.

  2006cites this paper
• Undermining tumor angiogenesis by gene therapy: an emerging field.

  2004cites this paper
• Detection of differential expression of mouse interferon-alpha subtypes by polymerase chain reaction using specific primers.

  2004cites this paper
• Interferon‐α and antisense K‐ras RNA combination gene therapy against pancreatic cancer

  2004cites this paper
• Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.

  2004cites this paper
• Foot-and-Mouth Disease

  2004cites this paper
• Novel Viral Disease Control Strategy: Adenovirus Expressing Alpha Interferon Rapidly Protects Swine from Foot-and-Mouth Disease

  2003cites this paper
• New approaches to rapidly control foot-and-mouth disease outbreaks

  2003cites this paper
• Interferon-alpha in tumor immunity and immunotherapy.

  2002cites this paper
• Tumor growth inhibition by interferon-alpha using PEGylated protein or adenovirus gene transfer with constitutive or regulated expression.

  2002cites this paper
• Foot-and-Mouth Disease Rapidly Protects Swine from Adenovirus Expressing Alpha Interferon Novel Viral Disease Control Strategy :

  2002cites this paper